Revenue (Tables)

6 Months Ended

Jun. 30, 2020

Risks and Uncertainties [Abstract]

Disaggregation of Revenue

The following table and description below shows the products from which the Company generated its revenue:

	Three Months Ended June 30,				Six Months Ended June 30,
Revenue by product (in thousands)	2020		2019		2020		2019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	9,790	$	12,989	$	21,218	$	22,776
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	2,819		3,459		6,335		6,202
Implants sold direct based on contracted rates (c)	1,806		3,450		4,916		6,676
Implants sold direct subject to third party reimbursement (d)	589		281		1,016		603
Biopsy kits - direct bill	348		557		811		1,099
Change in estimates related to prior periods (e)	(248)		87		1,095		50
Epicel
Direct bill (hospital)	4,910		5,328		11,301		10,555
Total revenue	$	20,014	$	26,151	$	46,692	$	47,961
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.

Schedules of concentration of risk

The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below.

	Revenue Concentration								Accounts Receivable Concentration
	Three Months Ended June 30,				Six Months Ended June 30,				June 30,		December 31,
	2020		2019		2020		2019		2020		2019
Epicel	6	%	6	%	10	%	8	%	3	%	2	%